Latest news with #QIAcuity
Yahoo
03-07-2025
- Business
- Yahoo
Qiagen Teams With Gencurix to Expand Digital PCR Cancer Assays
Qiagen N.V. (NYSE:QGEN) ranks among the best CRISPR stocks to buy. Qiagen N.V. (NYSE:QGEN) and Gencurix announced a collaboration on June 18 to provide oncology assays for Qiagen's QIAcuityDx digital PCR platform. The collaboration will focus on developing multiplex cancer assays for use in liquid and tissue biopsies. As the authorized manufacturer, Gencurix will create a number of cancer tests while striving to obtain IVD regulatory clearances. Following approval, Qiagen's global commercial infrastructure will be used for marketing the assays. The collaboration makes use of QIAGEN's QIAcuityDx platform, a member of the QIAcuity family of digital PCR technologies, which by the end of 2024 had achieved over 2,700 total placements. Furthermore, Qiagen N.V. (NYSE:QGEN) recently concluded the acquisition of Genoox for $70 million, with possible extra milestone payments, in order to improve its capacity for genetic data analysis. Qiagen's Digital Insights suite now incorporates Genoox's Franklin platform. A global leader in Sample to Insight solutions, Qiagen N.V. (NYSE:QGEN) offers tools for extracting and analyzing proteins, RNA, and DNA from a variety of samples. While we acknowledge the potential of QGEN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
18-06-2025
- Business
- Business Wire
QIAGEN and GENCURIX Announce QIAcuity Digital PCR IVD Assay Development Partnership
VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and GENCURIX, Inc. (KOSDAQ: 229000) today announced a new partnership to develop oncology assays for use on the QIAcuityDx platform, a high-performance digital PCR system designed for clinical diagnostics. GENCURIX is the first development partner under QIAGEN's QIAcuityDx Partnering Program. This important advancement marks a significant step towards establishing a broad menu of in vitro diagnostic (IVD) assays on the QIAcuityDx Four platform, increasing access to digital PCR diagnostics. The new partnership combines QIAGEN's QIAcuityDx digital PCR platform to advance sensitive, cost-effective oncology diagnostics with GENCURIX's expertise in multiplex assay development. The aim is to enable the creation of oncology IVD assays for both tissue and liquid biopsy applications, with flexible commercialization options and global reach through QIAGEN's Partnering Program. 'The QIAcuityDx Partnering Program is designed to enable the generation of a broad menu of IVD assays on the platform,' said Jonathan Arnold, Vice President and Head, Partnering for Precision Diagnostics at QIAGEN. 'The first partnership in this program with GENCURIX is an exciting moment, giving our oncology testing customers access to high-quality IVD assays that complement other established methods such as qPCR and NGS. We look forward to working with GENCURIX within this promising partner program.' 'This strategic partnership with QIAGEN represents a major inflection point for expanding our oncology molecular diagnostic technologies into the global market,' said Sang Rae Cho, CEO at GENCURIX. 'We are confident that the synergy between our diagnostic content and QIAGEN's platform will lead to global-standard precision cancer diagnostic solutions.' The QIAcuityDx Partnering Program aims to support third-party assay development on QIAcuityDx, which is a member of the QIAcuity family of digital PCR systems that reached at the end of 2024 more than 2,700 cumulative placements since launch. These menu initiatives for clinical applications will leverage this installed base as well as build on the 2024 milestone of launching more than 130 new assays for QIAcuity for research applications, and complemented by the extensive menu of custom assays available on QIAGEN's GeneGlobe platform at GENCURIX will apply its proven expertise in complex, multiplex IVD assay development to create oncology tests The QIAcuityDx Four platform delivers a scalable and high-performance digital PCR solution for clinical laboratories. As global adoption of digital PCR grows, it is increasingly recognized as a complementary method to qPCR and NGS—particularly in oncology, infectious diseases, and rare genetic disorders. Through the QIAcuityDx Partnering Program, QIAGEN is opening its platform to third-party developers, encouraging innovation in order to offer laboratories a continuously expanding range of validated diagnostic tests. GENCURIX will begin developing multiple oncology assays and pursue IVD regulatory approvals. GENCURIX, as the legal manufacturer of the assays, will be fully responsible for obtaining and maintaining all necessary regulatory approvals and certifications. Upon approval, the assays will be marketed through QIAGEN's global commercial infrastructure as part of the QIAcuityDx Partnering Program, ensuring streamlined access for laboratories worldwide. By enabling third-party development, QIAGEN is addressing the growing demand for broader access to high-precision and cost-efficient diagnostic assays. The collaboration with GENCURIX represents the first step in building a robust and innovative assay ecosystem for the QIAcuityDx platform, backed by QIAGEN's distribution capabilities and technical support. For more information about the QIAcuityDx Partnering Program please visit: About QIAGEN QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions, enabling customers to extract and gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis while bioinformatics software and knowledge bases can be used to interpret data to find actionable insights. Automation solutions bring these processes together into seamless and cost-effective workflows. QIAGEN serves over 500,000 customers globally in Life Sciences (academia, pharma R&D and industrial applications, primarily forensics) and Molecular Diagnostics for clinical healthcare. As of March 31, 2025, QIAGEN employed approximately 5,700 people in over 35 locations worldwide. For more information, visit About GENCURIX GENCURIX Inc. is a molecular diagnostics company based in Seoul, South Korea, focused on developing dPCR-based diagnostics and liquid biopsy platforms. Its products include GenesWell™ BCT, a breast cancer prognostic test, and Droplex™, a diagnostic assay series for companion and stratification testing in multiple cancer types. For more information, visit Forward-Looking Statement Certain statements in this press release may constitute forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements, including those regarding QIAGEN's products, development timelines, marketing and / or regulatory approvals, financial and operational outlook, growth strategies, collaborations and operating results - such as expected adjusted net sales and adjusted diluted earnings - are based on current expectations and assumptions. However, they involve uncertainties and risks. These risks include, but are not limited to, challenges in managing growth and international operations (including the effects of currency fluctuations, regulatory processes and logistical dependencies), variability in operating results, commercial development for our products to customers in the Life Sciences and clinical healthcare, changes in relationships with customers, suppliers or strategic partners; competition and rapid technological advancements; fluctuating demand for QIAGEN's products due to factors such as economic conditions, customer budgets and funding cycles; obtaining and maintaining regulatory approvals for our products; difficulties in successfully adapting QIAGEN's products into integrated solutions and producing these products; and protecting product differentiation from competitors. Additional uncertainties may arise from market acceptance of new products, integration of acquisitions, governmental actions, global or regional economic developments, natural disasters, political or public health crises, and other "force majeure" events. There is also no guarantee that anticipated benefits from restructuring programs and acquisitions will materialize as expected. For a comprehensive overview of risks, please refer to the 'Risk Factors' contained in our most recent Annual Report on Form 20-F and other reports filed with or furnished to the U.S. Securities and Exchange Commission.
Business Insider
06-06-2025
- Business
- Business Insider
Qiagen, Tracer Biotechnologies announce strategic partnership
Tracer Biotechnologies is pleased to announce a strategic partnership with Qiagen (QGEN) to co-develop and commercialize minimal residual disease assays for solid tumors on Qiagen's QIAcuity digital PCR platform. This collaboration aims to deliver highly sensitive, cost-effective, and decentralized MRD testing solutions that enable oncologists to monitor cancer recurrence and guide personalized treatment decisions using minimally invasive blood samples. Confident Investing Starts Here:
Yahoo
06-06-2025
- Business
- Yahoo
QGEN Stock to Gain From Expanding Oncology Portfolio via New Alliances
QIAGEN N.V. QGEN announced the expansion of its oncology diagnostics portfolio with two strategic partnerships. The new collaborations with Tracer Biotechnologies and Foresight Diagnostics are set to advance the use of minimal residual disease (MRD) testing in clinical trials to support pharma co-development projects for companion diagnostics (CDx). MRD testing is becoming a cornerstone of oncology by enabling early detection of cancer recurrence and guiding timely adjustments to therapy from a blood sample. The latest partnerships support the growing demand for decentralized, non-invasive tools that advance precision medicine and help deliver more personalized care. Following the announcement yesterday, shares of QIAGEN ended the session at $44.90, down 0.5% from the previous close. On a promising note, the company's MRD portfolio spans sample technologies and testing platforms that support workflows from sample to insight. These new partnerships represent an important step in strengthening QIAGEN's leadership in oncology by aiming to bring innovative MRD technologies into clinical practice. The focus is on enhancing scalable, cost-effective solutions based on the QIAcuity digital PCR (dPCR) system, enabling laboratories and healthcare providers worldwide to use MRD insights for guiding personalized treatment decisions for cancer patients. As a result, we expect the developments to positively boost the market sentiment toward QGEN stock. QIAGEN has a market capitalization of $10.03 billion. The company's earnings yield of 5.2% compares favorably to the industry average of -32.1% yield. In the trailing four quarters, it delivered an average earnings surprise of 4.9%. Tracer Biotechnologies, a developer of blood-based molecular diagnostics for cancer, is working with QIAGEN to create CDx for MRD testing in solid tumors. These assays, intended for QIAGEN's QIAcuity dPCR platform, enable the use of minimally invasive blood samples to monitor residual disease with high sensitivity. The approach offers a cost-efficient and quick way to support decentralized implementation in clinical laboratories with results comparable to those generated using next-generation sequencing technologies. Image Source: Zacks Investment Research Foresight Diagnostics is a pioneering cancer diagnostics company focused on developing ultra-sensitive liquid biopsy tests for MRD detection. Together with QIAGEN, both are creating a kit-based version of the Foresight CLARITY assay — a circulating tumor DNA (ctDNA)-based NGS test for certain types of lymphoma. Transitioning the assay from a CLIA central laboratory service to an in-lab kit is designed to allow for broader clinical access and support pharmaceutical-sponsored trials with companion diagnostic applications. Per a research report, the global cancer diagnostics market was valued at $109.61 billion in 2024 and is expected to grow at a compound annual rate of 6.1% through 2030. The growing prevalence of cancer, technological advancements in diagnostics procedures and rising initiatives undertaken by private & public organizations are fueling the market's growth. Last month, QIAGEN announced a new commercial partnership and co-marketing agreement with ID Solutions — a French provider of high-quality dPCR assays and customized molecular testing solutions for oncology and other disease areas — to expand the availability of dPCR assays for oncology research applications. In the past six months, QGEN shares have dropped 0.3% compared with the industry's 11.7% decline. QIAGEN currently carries a Zacks Rank #2 (Buy). Some other top-ranked stocks in the broader medical space are Phibro Animal Health PAHC, Hims & Hers Health HIMS and Cencora COR. While Phibro Animal Health sports a Zacks Rank #1 (Strong Buy) at present, Hims & Hers Health and Cencora each carry a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank stocks here. Estimates for Phibro Animal Health's fiscal 2025 earnings per share have jumped 3.6% to $2.01 in the past 30 days. Shares of the company have rallied 36.2% in the past year compared with the industry's 10.5% growth. Its earnings yield of 8.7% compares comfortably with the industry's 0.5% yield. PAHC's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 30.6%. Hims & Hers Health shares have surged 176% in the past year. Estimates for the company's 2025 earnings per share have jumped 12.5% to 72 cents in the past 30 days. HIMS' earnings beat estimates twice in the trailing four quarters, matched in one and missed on another occasion, the average surprise being 19.6%. In the last reported quarter, it posted an earnings surprise of 66.7%. Estimates for Cencora's fiscal 2025 earnings per share have increased 2.5% to $15.75 in the past 30 days. Shares of the company have jumped 26.4% in the past year against the industry's 21% fall. COR's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6%. In the last reported quarter, it delivered an earnings surprise of 8.3%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report QIAGEN N.V. (QGEN) : Free Stock Analysis Report Cencora, Inc. (COR) : Free Stock Analysis Report Phibro Animal Health Corporation (PAHC) : Free Stock Analysis Report Hims & Hers Health, Inc. (HIMS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
05-06-2025
- Business
- Yahoo
Tracer Biotechnologies Announces Strategic Partnership with QIAGEN to Advance Blood-Based MRD Testing for Solid Tumors
NEW YORK, June 05, 2025--(BUSINESS WIRE)--Tracer Biotechnologies, a leader in blood-based molecular diagnostics for cancer, is pleased to announce a strategic partnership with QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) to co-develop and commercialize minimal residual disease (MRD) assays for solid tumors on QIAGEN's QIAcuity digital PCR platform. This collaboration aims to deliver highly sensitive, cost-effective, and decentralized MRD testing solutions that enable oncologists to monitor cancer recurrence and guide personalized treatment decisions using minimally invasive blood samples. "Partnering with QIAGEN enables Tracer to bring our solid tumor MRD expertise to a broader market using a robust digital PCR platform in QIAcuity," said Mark Kaganovich, CEO of Tracer Biotechnologies. "With QIAcuity's sensitivity and scalability, we can deliver high-quality companion diagnostics that integrate seamlessly into clinical workflows and offer new options to oncologists and patients." Tracer offers two complementary MRD solutions: Tracer dPCR, a tumor-informed, multiplexed digital PCR assay that allows institutions to run bespoke MRD tests internally using their own digital PCR instruments; Tracer WGS, an AI-powered whole-genome ctDNA platform that enables ultra-sensitive tumor-agnostic detection and tracking with no need for prior tissue. "This new partnership represents an important step in further establishing QIAGEN's major role in oncology. We are bringing innovative MRD technologies into drug development through our companion diagnostic partnerships," said Jonathan Arnold, Vice President, Head of Partnering for Precision Diagnostics at QIAGEN. "In particular, we want to strengthen our scalable, cost-effective solutions based on our QIAcuity digital PCR system and enable our pharmaceutical partners to use MRD insights for guiding personalized treatment decisions for cancer patients." Tracer's mission is to turn every digital PCR machine and next-generation sequencer into a sensitive MRD assay—empowering institutions, pharmaceutical companies, and clinicians with the tools to decentralize testing, accelerate treatment decisions, and personalize cancer care. About Tracer Biotechnologies Tracer Biotechnologies is a molecular diagnostics company specializing in blood-based assays for cancer detection and monitoring. Our platform enables decentralized, high-performance MRD testing using either digital PCR or whole-genome sequencing—bringing precision oncology closer to the point of care. For more information visit About QIAGEN QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions, enabling customers to extract and gain valuable molecular insights from samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis while bioinformatics software and knowledge bases can be used to interpret data to find actionable insights. Automation solutions bring these processes together into seamless and cost-effective workflows. QIAGEN serves over 500,000 customers globally in Life Sciences (academia, pharma R&D and industrial applications, primarily forensics) and Molecular Diagnostics for clinical healthcare. As of March 31, 2025, QIAGEN employed approximately 5,700 people in over 35 locations worldwide. For more information, visit View source version on Contacts communications@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
